Enanta Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Enanta Pharmaceuticals

09/08/2022 14:24

* Enanta Pharmaceuticals Inc  ENTA.OQ  reported a quarterly
adjusted loss of $1.53​​ per share for the quarter ended in
June. The mean expectation of eight analysts for the quarter was
for a loss of $1.39 per share.
    * Revenue fell 9.9% to $19.48 million from a year ago;
analysts
expected $20.70 million. 
    * Enanta Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.53​.
    * The mean earnings estimate of analysts had risen by
about 3.3%
in the last three months.​ 
    * In the last 30 days one analyst negatively revised an
earnings
estimate 
    * Enanta Pharmaceuticals Inc shares had risen by 50.8% this
quarter and lost 4.7% so far this year.
    * The company reported a quarterly loss of $31.7 million.
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $70.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 9
at 01:23 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -1.39          -1.53          Missed
 Mar. 31 2022      -1.43          -1.63          Missed
 Dec. 31 2021      -1.08          -1.48          Missed
 Sep. 30 2021      -1.22          -1.22          Met